We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

GEMOX Active With Low Toxicity in Pancreatic Cancer

Nov 1, 2001
Volume: 
10
Issue: 
11
  • Gastrointestinal Cancer, Pancreatic Cancer

SAN FRANCISCO—In patients with advanced pancreatic cancer, the
combination of gemcitabine (Gemzar) followed by oxaliplatin (investigational in
the United States) (GEMOX) is active with low toxicity, Christophe Louvet, MD,
Hôpital St-Antoine, Paris, France, said at the 37th Annual Meeting of the
American Society of Clinical Oncology (ASCO abstract 506).

The rationale for the gemcitabine/oxaliplatin combination is that the two
agents have distinctly different mechanisms of action and patterns of
resistance without overlapping toxicities.

Preclinical investigations looking into the possible combined effects of
gemcitabine/oxaliplatin or gemcitabine/cisplatin (Platinol) found the best
synergy effects for the sequence of gemcitabine followed by oxaliplatin, Dr.
Louvet said.

The current phase II trial included 64 patients (mean age, 59.5 years)
treated at eight centers; 47% had stage II-III locally advanced disease and 53%
had stage IV metastatic disease. Enrollment criteria included Karnofsky
performance status of 60 to 100.

The Regimen

Patients received gemcitabine 1,000 mg/m² in a 10 mg/m²/min infusion on
day 1 and oxaliplatin 100 mg/m² in a 2-hour infusion on day 2. Treatment was
repeated every 2 weeks for six cycles followed by chemoradiation with
fluorouracil in locally advanced patients, or until progression of disease in
metastatic patients.

Partial responses were reported in 19 patients, stable disease in 28, and
progressive disease in 16, for a response rate of 30.2%. Response rates for
locally advanced patients (31%) and metastatic disease patients (30.3%) were
similar. The clinical benefit response rate was 39.7% (23 of 58 patients), Dr.
Louvet said.

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Related Articles

  • ctDNA Increase May Predict Regorafenib Response in Advanced CRC
  • Inhibit CXCR4 to Treat CRC and Pancreatic Cancer
  • Short-Acting CCBs May Increase Risk of Pancreatic Cancer
  • A3AR Agonists May Help Prevent Chemotherapy-Induced Neuropathic Pain
  • Deep Learning–Based Tissue Analysis May Benefit Colorectal Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.